戻る
「早戻しボタン」を押すと検索画面に戻ります。 [閉じる]

コーパス検索結果 (１語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します
1 further prostaglandin production and further uterine contraction.
2 ate of the myometrium, and PGR-A facilitates uterine contraction.
3 hin the trophoblast as well as a trigger for uterine contraction.
4 s and calcium entry, which may contribute to uterine contraction.
5 ace electrodes has been attempted to monitor uterine contraction.
6 nd METx (100 nM) had no effect on OT induced uterine contractions.
7 tocia), suggesting that it is detrimental to uterine contractions.
8 tal membrane rupture, cervical ripening, and uterine contractions.
9 1) and admission to the hospital for preterm uterine contractions (50% vs 9%; P = .002).
10 ding uterus, WIN2 dose-dependently increased uterine contraction amplitude.
11 ffects only after HYPX, reducing both MT and uterine contraction amplitude.
12 noid receptor agonist WIN 55,212-2 (WIN2) on uterine contractions (amplitude and rate) and micturitio
13                     Prostaglandins stimulate uterine contractions and are clinically used for cervica
14 lished roles of oxytocin (OT) is in inducing uterine contractions and labor.
15    METx (41 nM) had no effect on spontaneous uterine contractions and METx (100 nM) had no effect on
16                                PGs stimulate uterine contractions and prepare the cervix for parturit
17 ezo1 and Piezo2 in mice resulted in weakened uterine contractions and severe parturition defects.
18 onapeptide hormone used in labor to initiate uterine contractions and to prevent and treat postpartum
19 lular factors, targeted by drugs to regulate uterine contractions, and tissue level electromechanical
20 eight, frequency of prenatal visits, preterm uterine contractions, antepartum hemorrhages, placenta p
21            The mechanisms used to coordinate uterine contractions are not known.
22                 We assessed the frequency of uterine contractions as a predictor of the risk of spont
23 ide detailed 3D images and quantification of uterine contractions as well as novel insights into the
24                                         Each uterine contraction begins with a regional contraction,
25 re monitoring of the fetal condition and the uterine contractions can be guaranteed, routine disconti
26 ic signals mediated by OT and PGs to promote uterine contractions, cervix softening, and membrane rup
27 ain targets of pharmaceutical treatments for uterine contraction disorders.
28 more efficient pharmaceutical treatments for uterine contraction disorders.
29 raoptic and paraventricular nuclei to induce uterine contractions during birth.
30                               In addition to uterine contractions during labor and milk ejection duri
31                                              Uterine contractions during labor are known to be associ
32 ometrial activation is required to establish uterine contractions during labor.
33 den infant death syndrome and for regulating uterine contractions during labor.
34 s on the occurrence of precisely coordinated uterine contractions during labour.
35 uitary gland into the circulation to trigger uterine contractions during parturition.
36 targeting uterine cells in-vitro, inhibiting uterine contractions ex-vivo, while doubling uterine dru
37          The measurement of the frequency of uterine contractions has not been useful for reducing th
38                 Treatment intended to reduce uterine contractions include tocolytic agents, such as i
39                                              Uterine contraction is a central feature of PTB, so gain
40                      Preterm labor caused by uterine contractions is a major contributor to neonatal
41                         The onset of preterm uterine contractions is preceded by asymptomatic cervica
42 preterm labour, but their ability to repress uterine contractions lasts </= 48 h and their use does n
43 ery increases with an increased frequency of uterine contractions, measurement of this frequency is n
44                                   Pre-labour uterine contractions, occurring throughout pregnancy, ar
45 ng of the heart rate well after the onset of uterine contractions (odds ratio, 3.9; 95 percent confid
46 nding event points (EP) from the FHR and the Uterine Contraction Pressure (UCP).
47 potheses formed to explain the regulation of uterine contraction/relaxation.
48 ceptor agonists that act via cAMP can reduce uterine contractions to delay preterm labour, but their
49                                              Uterine contractions, triggered by prostaglandins, excit
50                                              Uterine contraction (UC) is an essential clinical indica
51                                  The regular uterine contractions were recorded via a balloon cathete